For Immediate Release 1 February 2007 BioProgress plc Operational Board Update and Appointment London, UK, 1 February 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharmaceutical and healthcare company, today announces the creation of a new executive operational board for the Company, and the appointment of Keith Hemming, as Head of Operations, a new position within the management team of BioProgress. The operational board will be responsible for the day to day management of the Group. This has become necessary as the number of new development projects both for partners and for the Company's own pharmaceutical division is increasing substantially due to positive validation work and the adoption of a number of BioProgress's enabling systems. At the same time the core pharmaceutical division Dexo is undergoing rapid growth in all of its territories. This underlying organic growth validates the Company's product led strategy and creates the resource necessary for continued substantial growth. Keith Hemming, the new Head of Operations, has over twenty years experience in the Pharmaceutical industry, holding senior marketing and General Management positions with Squibb, Yamanouchi, and most recently as President UK Operations for Fujisawa Pharma, member of the Fujisawa European senior management team. Prior to this he was with Astellas Pharmaceuticals Global Licensee Division working on European strategy and implementation. During his career he launched Flomax and Protopic in the UK, and took Prograf, an immunosuppressant, to market leadership. Keith was a member of the Board of Management of the Association of British Pharmaceutical Industry (ABPI) for four years, and member of the UK Pharmaceutical Code of Practice Appeal Board. He was also founder and first Chair of the UK Japanese Pharmaceutical Group associated to the Japanese Pharmaceutical Manufacturers Association (JPMA), and Chair of the Industry Group for the National Health Service Framework for Renal Services. Richard Trevillion, Chief Executive Officer, BioProgress Plc, said: "We are pleased to welcome Keith to the operational management team. Keith has substantial experience in sales and marketing and in managing high growth late stage pharmaceutical product development. His knowledge of the Japanese pharmaceutical industry is also welcome as BioProgress increases its marketing activity within Japan. " Keith Hemming, Head of Operations, said: "I am delighted to be joining BioProgress at such an exciting stage in the Company's development. The recent increase in activity is testament to the strength of the core enabling systems which are contributing to a strong product development pipeline. The resulting rapid growth in the Dexo pharmaceutical sales and marketing division validates the product led speciality pharmaceutical model that BioProgress is proactively pursuing." For further information: BioProgress Plc + 44 (0) 20 7098 9881 Richard Trevillion, CEO Steve Martin, CDO Hiral Patel, CFO Buchanan Communications + 44 (0) 20 7466 5000 Rebecca Skye Dietrich/Mark Court About BioProgress BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a vertically integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGELTM polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com Forward-Looking Information. The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company's filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions. This information is provided by RNS The company news service from the London Stock Exchange
Cambridgeshire -- (MARKET WIRE) -- February 1, 2007 --